Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Surgery Today
Published in: Surgery Today 4/2013

01-04-2013 | Review Article

Management of Barrett’s esophageal carcinoma

Authors: Tatsuya Miyazaki, Takanori Inose, Naritaka Tanaka, Takehiko Yokobori, Shigemasa Suzuki, Daigo Ozawa, Makoto Sohda, Masanobu Nakajima, Minoru Fukuchi, Hiroyuki Kato, Hiroyuki Kuwano

Published in: Surgery Today | Issue 4/2013

Login to get access

Abstract

Barrett’s esophagus (BE) is the premalignant lesion from which esophageal adenocarcinoma near the esophagogastric junction arises. The management of BE and the treatment of Barrett’s esophageal adenocarcinoma (BEA) are important clinical issues in Europe and the United States. As the Helicobacter pylori infection rate in Japan is decreasing in the younger population, the incidence of BE and adenocarcinoma arising from BE may start increasing. Thus, we review the current status of BEA and its management. Magnifying endoscopy with narrow-band imaging is important for diagnosing dysplasia arising from BE. In Japan, adenocarcinoma arising from BE is managed the same way as squamous cell carcinoma in the same location. Strategies to prevent BEA may include medication such as non-steroidal anti-inflammatory drugs and proton pump inhibitors, and anti-reflux surgery. Understanding the pathophysiology of BE will help to reduce the incidence of BEA.
Literature
1.
Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340(11):825–31.PubMedCrossRef
2.
Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83(10):2049–53.PubMedCrossRef
3.
Hoshihara Y, Kogure T, Yamamoto T, Hashimoto M, Hoteya O. Endoscopic diagnosis of Barrett’s esophagus. Nihon Rinsho. 2005;63(8):1394–8.PubMed
4.
Sharma P, Dent J, Armstrong D, Bergman JJ, Gossner L, Hoshihara Y, et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria. Gastroenterology. 2006;131(5):1392–9.PubMedCrossRef
5.
Japan Esophageal Society. Japanese Classification Esophageal Society. 10th ed. Tokyo: Kanehara & Co., Ltd.; 2008.
6.
Kinjo T, Kusano C, Oda I, Gotoda T. Prague C&M and Japanese criteria: shades of Barrett’s esophagus endoscopic diagnosis. J Gastroenterol. 2010;45(10):1039–44.PubMedCrossRef
7.
Barrett NR. Chronic peptic ulcer of the oesophagus and ‘oesophagitis’. Br J Surg. 1950;38(150):175–82.PubMedCrossRef
8.
Allison PR, Johnstone AS. The oesophagus lined with gastric mucous membrane. Thorax. 1953;8(2):87–101.PubMedCrossRef
9.
Barrett NR. The lower esophagus lined by columnar epithelium. Surgery. 1957;41(6):881–94.PubMed
10.
Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol. 2008;103(3):788–97.PubMedCrossRef
11.
Takubo K, Nixon JM, Jass JR. Ducts of esophageal glands proper and paneth cells in Barrett’s esophagus: frequency in biopsy specimens. Pathology. 1995;27(4):315–7.PubMedCrossRef
12.
Takubo K, Vieth M, Aryal G, Honma N, Sawabe M, Arai T, et al. Islands of squamous epithelium and their surrounding mucosa in columnar-lined esophagus: a pathognomonic feature of Barrett’s esophagus? Hum Pathol. 2005;36(3):269–74.PubMedCrossRef
13.
14.
Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett’s esophagus? Gastroenterology. 2000;119(2):333–8.PubMedCrossRef
15.
Pohl H, Welch HG. The role of over diagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97(2):142–6.PubMedCrossRef
16.
Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev. 2010;19(6):1468–70.PubMedCrossRef
17.
The Japanese Society for Esophageal Disease. Comprehensive Registry for Esophageal Cancer in Japan. 3rd ed; 2002.
18.
Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15(5):872–8.PubMedCrossRef
19.
Shibata A, Matsuda T, Ajiki W, Sobue T. Trend in incidence of adenocarcinoma of the esophagus in Japan, 1993–2001. Jpn J Clin Oncol. 2008;38(7):464–8.PubMedCrossRef
20.
The Japanese Society for Esophageal Disease, Comprehensive Registry of Esophageal Cancer in Japan 1998, r. e., Clinical Result of Patients treated with Endoscopically in 1998; 2002.
21.
The Japan Esophageal Society. Comprehensive Registry of Esophageal Cancer in Japan, 2001; 2009.
22.
The Japanese Society for Esophageal Disease, Comprehensive Registry of Esophageal Cancer in Japan (1988–1994). 1st ed; 2000.
23.
The Japanese Society for Esophageal Disease. Comprehensive Registry of Esophageal Cancer in Japan (1995, 1996, 1997). 2nd ed; 2001.
24.
The Japan Esophageal Society. Comprehensive Registry of Esophageal Cancer in Japan, 2002; 2010.
25.
The Japan Esophageal Society. Comprehensive Registry of Esophageal Cancer in Japan, 2003; 2011.
26.
Kazui T, Wada H, Fujita H. Thoracic and cardiovascular surgery in Japan during 2003: annual report by The Japanese Association for Thoracic Surgery. Jpn J Thorac Cardiovasc Surg. 2005;53(9):517–36.PubMedCrossRef
27.
Sakata R, Fujii Y, Kuwano H. Thoracic and cardiovascular surgery in Japan during 2008: annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2010;58(7):356–83.PubMedCrossRef
28.
Sakata R, Fujii Y, Kuwano H. Thoracic and cardiovascular surgery in Japan during 2009: annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2011;59(9):636–67.PubMedCrossRef
29.
Ueda Y, Fujii Y, Kuwano H. Thoracic and cardiovascular surgery in Japan during 2007. Annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2009;57(9):488–513.PubMedCrossRef
30.
Ueda Y, Fujii Y, Udagawa H. Thoracic and cardiovascular surgery in Japan during 2006: annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2008;56(7):365–88.PubMedCrossRef
31.
Ueda Y, Osada H, Osugi H. Thoracic and cardiovascular surgery in Japan during 2005. Annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2007;55(9):377–99.PubMedCrossRef
32.
Kazui T, Osada H, Fujita H. Thoracic and cardiovascular surgery in Japan during 2004. Jpn J Thorac Cardiovasc Surg. 2006;54(8):363–85.PubMedCrossRef
33.
Eloubeidi MA, Provenzale D. Clinical and demographic predictors of Barrett’s esophagus among patients with gastroesophageal reflux disease: a multivariable analysis in veterans. J Clin Gastroenterol. 2001;33(4):306–9.PubMedCrossRef
34.
Thomas T, Abrams KR, De Caestecker JS, Robinson RJ. Meta analysis: cancer risk in Barrett’s oesophagus. Aliment Pharmacol Ther. 2007;26(11–12):1465–77.PubMedCrossRef
35.
Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Eskes SA, Meuwissen SG. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol. 1999;94(4):884–7.PubMedCrossRef
36.
Weston AP, Badr AS, Topalovski M, Cherian R, Dixon A, Hassanein RS. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett’s esophagus, Barrett’s dysplasia, and Barrett’s adenocarcinoma. Am J Gastroenterol. 2000;95(2):387–94.PubMedCrossRef
37.
Lord RV, Frommer DJ, Inder S, Tran D, Ward RL. Prevalence of Helicobacter pylori infection in 160 patients with Barrett’s oesophagus or Barrett’s adenocarcinoma. Aust N Z J Surg. 2000;70(1):26–33.PubMedCrossRef
38.
Miwa K, Sahara H, Segawa M, Kinami S, Sato T, Miyazaki I, et al. Reflux of duodenal or gastro-duodenal contents induces esophageal carcinoma in rats. Int J Cancer. 1996;67(2):269–74.PubMedCrossRef
39.
Mutoh H, Hakamata Y, Sato K, Eda A, Yanaka I, Honda S, et al. Conversion of gastric mucosa to intestinal metaplasia in Cdx2-expressing transgenic mice. Biochem Biophys Res Commun. 2002;294(2):470–9.PubMedCrossRef
40.
Mutoh H, Sakurai S, Satoh K, Osawa H, Hakamata Y, Takeuchi T, et al. Cdx1 induced intestinal metaplasia in the transgenic mouse stomach: comparative study with Cdx2 transgenic mice. Gut. 2004;53(10):1416–23.PubMedCrossRef
41.
Zagorowicz E, Jankowski J. Molecular changes in the progression of Barrett’s oesophagus. Postgrad Med J. 2007;83(982):529–35.PubMedCrossRef
42.
Lao-Sirieix P, Lovat L, Fitzgerald RC. Cyclin A immunocytology as a risk stratification tool for Barrett’s esophagus surveillance. Clin Cancer Res. 2007;13(2 Pt 1):659–65.PubMedCrossRef
43.
Coppola D, Schreiber RH, Mora L, Dalton W, Karl RC. Significance of Fas and retinoblastoma protein expression during the progression of Barrett’s metaplasia to adenocarcinoma. Ann Surg Oncol. 1999;6(3):298–304.PubMedCrossRef
44.
Paulson TG, Galipeau PC, Xu L, Kissel HD, Li X, Blount PL, et al. p16 mutation spectrum in the premalignant condition Barrett’s esophagus. PLoS ONE. 2008;3(11):e3809.PubMedCrossRef
45.
Younes M, Lebovitz RM, Lechago LV, Lechago J. p53 protein accumulation in Barrett’s metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology. 1993;105(6):1637–42.PubMed
46.
Sikkema M, Kerkhof M, Steyerberg EW, Kusters JG, van Strien PM, Looman CW, et al. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett’s esophagus: a case-control study. Am J Gastroenterol. 2009;104(11):2673–80.PubMedCrossRef
47.
O’Riordan JM, Abdel-latif MM, Ravi N, McNamara D, Byrne PJ, McDonald GS, et al. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol. 2005;100(6):1257–64.PubMedCrossRef
48.
Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE. Cyclooxygenase-2 expression in the Barrett’s metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol. 2001;96(4):990–6.PubMed
49.
Osterheld MC, Bian YS, Bosman FT, Benhattar J, Fontolliet C. Beta-catenin expression and its association with prognostic factors in adenocarcinoma developed in Barrett esophagus. Am J Clin Pathol. 2002;117(3):451–6.PubMedCrossRef
50.
Washington K, Chiappori A, Hamilton K, Shyr Y, Blanke C, Johnson D, et al. Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett’s esophagus and esophageal adenocarcinomas. Mod Pathol. 1998;11(9):805–13.PubMed
51.
Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett’s esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol. 2000;95(7):1669–76.PubMed
52.
Dorer R, Odze RD. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett’s esophagus, ulcerative colitis, and Crohn’s disease. Am J Surg Pathol. 2006;30(7):871–7.PubMedCrossRef
53.
Moyes LH, Going JJ. Still waiting for predictive biomarkers in Barrett’s oesophagus. J Clin Pathol. 2011;64(9):742–50.PubMedCrossRef
54.
Meyer W, Vollmar F, Bar W. Barrett-esophagus following total gastrectomy. A contribution to it’s pathogenesis. Endoscopy. 1979;11(2):121–6.
55.
Avidan B, Sonnenberg A, Schnell TG, Sontag SJ. Gastric surgery is not a risk for Barrett’s esophagus or esophageal adenocarcinoma. Gastroenterology. 2001;121(6):1281–5.PubMedCrossRef
56.
Akiyama T, Inamori M, Akimoto K, Iida H, Endo H, Hosono K, et al. Gastric surgery is not a risk factor for erosive esophagitis or Barrett’s esophagus. Scand J Gastroenterol. 2010;45(4):403–8.PubMedCrossRef
57.
Paull A, Trier JS, Dalton MD, Camp RC, Loeb P, Goyal RK. The histologic spectrum of Barrett’s esophagus. N Engl J Med. 1976;295(9):476–80.PubMedCrossRef
58.
Falk GW, Ours TM, Richter JE. Practice patterns for surveillance of Barrett’s esophagus in the United States. Gastrointest Endosc. 2000;52(2):197–203.PubMedCrossRef
59.
Gross CP, Canto MI, Hixson J, Powe NR. Management of Barrett’s esophagus: a national study of practice patterns and their cost implications. Am J Gastroenterol. 1999;94(12):3440–7.PubMedCrossRef
60.
Canto MI, Setrakian S, Willis J, Chak A, Petras R, Powe NR, et al. Methylene blue-directed biopsies improve detection of intestinal metaplasia and dysplasia in Barrett’s esophagus. Gastrointest Endosc. 2000;51(5):560–8.PubMedCrossRef
61.
Horwhat JD, Maydonovitch CL, Ramos F, Colina R, Gaertner E, Lee H, et al. A randomized comparison of methylene blue-directed biopsy versus conventional four-quadrant biopsy for the detection of intestinal metaplasia and dysplasia in patients with long-segment Barrett’s esophagus. Am J Gastroenterol. 2008;103(3):546–54.PubMedCrossRef
62.
Sharma P, Weston AP, Topalovski M, Cherian R, Bhattacharyya A, Sampliner RE. Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett’s oesophagus. Gut. 2003;52(1):24–7.PubMedCrossRef
63.
Yuki T, Amano Y, Kushiyama Y, Takahashi Y, Ose T, Moriyama I, et al. Evaluation of modified crystal violet chromoendoscopy procedure using new mucosal pit pattern classification for detection of Barrett’s dysplastic lesions. Dig Liver Dis. 2006;38(5):296–300.PubMedCrossRef
64.
Guelrud M, Herrera I, Essenfeld H, Castro J. Enhanced magnification endoscopy: a new technique to identify specialized intestinal metaplasia in Barrett’s esophagus. Gastrointest Endosc. 2001;53(6):559–65.PubMedCrossRef
65.
Sharma P, McQuaid K, Dent J, Fennerty MB, Sampliner R, Spechler S, et al. A critical review of the diagnosis and management of Barrett’s esophagus: the AGA Chicago Workshop. Gastroenterology. 2004;127(1):310–30.PubMedCrossRef
66.
Hirota WK, Zuckerman MJ, Adler DG, Davila RE, Egan J, Leighton JA, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc. 2006;63(4):570–80.PubMedCrossRef
67.
Playford RJ. New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett’s oesophagus. Gut. 2006;55(4):442.PubMedCrossRef
68.
Asaoka D, Nagahara A, Oguro M, Kurosawa A, Osada T, Kawabe M, et al. Utility of autofluorescence imaging video endoscopy in screening for Barrett’s esophagus. Endoscopy. 2009;41(Suppl 2):E113.PubMedCrossRef
69.
Kara MA, Bergman JJ. Autofluorescence imaging and narrow-band imaging for the detection of early neoplasia in patients with Barrett’s esophagus. Endoscopy. 2006;38(6):627–31.PubMedCrossRef
70.
Curvers WL, Singh R, Song LM, Wolfsen HC, Ragunath K, Wang K, et al. Endoscopic tri-modal imaging for detection of early neoplasia in Barrett’s oesophagus: a multi-centre feasibility study using high-resolution endoscopy, autofluorescence imaging and narrow band imaging incorporated in one endoscopy system. Gut. 2008;57(2):167–72.PubMedCrossRef
71.
Jobe BA, Hunter JG, Chang EY, Kim CY, Eisen GM, Robinson JD, et al. Office-based unsedated small-caliber endoscopy is equivalent to conventional sedated endoscopy in screening and surveillance for Barrett’s esophagus: a randomized and blinded comparison. Am J Gastroenterol. 2006;101(12):2693–703.PubMedCrossRef
72.
Rubenstein JH, Inadomi JM, Brill JV, Eisen GM. Cost utility of screening for Barrett’s esophagus with esophageal capsule endoscopy versus conventional upper endoscopy. Clin Gastroenterol Hepatol. 2007;5(3):312–8.PubMedCrossRef
73.
Kadri SR, Lao-Sirieix P, O’Donovan M, Debiram I, Das M, Blazeby JM, et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett’s oesophagus in primary care: cohort study. BMJ. 2010;341:c4372.PubMedCrossRef
74.
Mannath J, Subramanian V, Hawkey CJ, Ragunath K. Narrow band imaging for characterization of high grade dysplasia and specialized intestinal metaplasia in Barrett’s esophagus: a meta-analysis. Endoscopy. 2010;42(5):351–9.PubMedCrossRef
75.
Singh R, Anagnostopoulos GK, Yao K, Karageorgiou H, Fortun PJ, Shonde A, et al. Narrow-band imaging with magnification in Barrett’s esophagus: validation of a simplified grading system of mucosal morphology patterns against histology. Endoscopy. 2008;40(6):457–63.PubMedCrossRef
76.
Sharma P, Hawes RH, Bansal A, Gupta N, Curvers W, Rastogi A, et al. Standard endoscopy with random biopsies versus narrow band imaging targeted biopsies in Barrett’s oesophagus: a prospective, international, randomised controlled trial. Gut; 2012.
77.
Bollschweiler E, Baldus SE, Schroder W, Prenzel K, Gutschow C, Schneider PM, et al. High rate of lymph-node metastasis in submucosal esophageal squamous-cell carcinomas and adenocarcinomas. Endoscopy. 2006;38(2):149–56.PubMedCrossRef
78.
Gockel I, Domeyer M, Sgourakis GG, Schimanski CC, Moehler M, Kirkpatrick CJ, et al. Prediction model of lymph node metastasis in superficial esophageal adenocarcinoma and squamous cell cancer including D2–40 immunostaining. J Surg Oncol. 2009;100(3):191–8.PubMedCrossRef
79.
Seewald S, Ang TL, Soehendra N. Endoscopic mucosal resection of Barrett’s oesophagus containing dysplasia or intramucosal cancer. Postgrad Med J. 2007;83(980):367–72.PubMedCrossRef
80.
Pech O, Behrens A, May A, Nachbar L, Gossner L, Rabenstein T, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut. 2008;57(9):1200–6.PubMedCrossRef
81.
Ikeda K, Isomoto H, Oda H, Shikuwa S, Mizuta Y, Iwasaki K, et al. Endoscopic submucosal dissection of a minute intramucosal adenocarcinoma in Barrett’s esophagus. Dig Endosc. 2009;21(1):34–6.PubMedCrossRef
82.
Van Laethem JL, Jagodzinski R, Peny MO, Cremer M, Deviere J. Argon plasma coagulation in the treatment of Barrett’s high-grade dysplasia and in situ adenocarcinoma. Endoscopy. 2001;33(3):257–61.PubMedCrossRef
83.
Wolfsen HC, Hemminger LL, Wallace MB, Devault KR. Clinical experience of patients undergoing photodynamic therapy for Barrett’s dysplasia or cancer. Aliment Pharmacol Ther. 2004;20(10):1125–31.PubMedCrossRef
84.
Sharma P, Jaffe PE, Bhattacharyya A, Sampliner RE. Laser and multipolar electrocoagulation ablation of early Barrett’s adenocarcinoma: long-term follow-up. Gastrointest Endosc. 1999;49(4 Pt 1):442–6.PubMedCrossRef
85.
van de Ven C, De Leyn P, Coosemans W, Van Raemdonck D, Lerut T. Three-field lymphadenectomy and pattern of lymph node spread in T3 adenocarcinoma of the distal esophagus and the gastro-esophageal junction. Eur J Cardiothorac Surg. 1999;15(6):769–73.PubMedCrossRef
86.
Altorki N, Kent M, Ferrara C, Port J. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg. 2002;236(2):177–83.PubMedCrossRef
87.
Gockel I, Sgourakis G, Lyros O, Polotzek U, Schimanski CC, Lang H, et al. Risk of lymph node metastasis in submucosal esophageal cancer: a review of surgically resected patients. Expert Rev Gastroenterol Hepatol. 2011;5(3):371–84.PubMedCrossRef
88.
Ancona E, Rampado S, Cassaro M, Battaglia G, Ruol A, Castoro C, et al. Prediction of lymph node status in superficial esophageal carcinoma. Ann Surg Oncol. 2008;15(11):3278–88.PubMedCrossRef
89.
Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347(21):1662–9.PubMedCrossRef
90.
Omloo JM, Lagarde SM, Hulscher JB, Reitsma JB, Fockens P, van Dekken H, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg. 2007; 246(6):992–1000; discussion 1000–1.
91.
Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681–92.PubMedCrossRef
92.
Network®, N.C.C., NCCN Clinical Practice Guidelines in Oncology™ Esophageal Cancer V.2.2010; 2010.
93.
Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85–01). Radiation Therapy Oncology Group. JAMA. 1999;281(17):1623–7.PubMedCrossRef
94.
Lerut T, Coosemans W, van Raemdonck D, Dillemans B, De Leyn P, Marnette JM, et al. Surgical treatment of Barrett’s carcinoma. Correlations between morphologic findings and prognosis. J Thorac Cardiovasc Surg. 1994; 107(4):1059–65; discussion 1065–6.
95.
Peracchia A, Bonavina L, Via A, Incarbone R. Current trends in the surgical treatment of esophageal and cardia adenocarcinoma. J Exp Clin Cancer Res. 1999;18(3):289–94.PubMed
96.
Mariette C, Finzi L, Piessen G, Van Seuningen I, Triboulet JP. Esophageal carcinoma: prognostic differences between squamous cell carcinoma and adenocarcinoma. World J Surg. 2005;29(1):39–45.PubMedCrossRef
97.
Gertler R, Stein HJ, Langer R, Nettelmann M, Schuster T, Hoefler H, et al. Long-term outcome of 2920 patients with cancers of the esophagus and esophagogastric junction: evaluation of the New Union Internationale Contre le Cancer/American Joint Cancer Committee staging system. Ann Surg. 2011;253(4):689–98.PubMedCrossRef
98.
Zingg U, Montani M, Busch M, Metzger U, Went P, Oertli D. Prognostic influence of immunohistochemically detected lymph node micrometastasis and histological subtype in pN0 oesophageal cancer. Eur J Surg Oncol. 2009;35(6):593–9.PubMedCrossRef
99.
Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology. 2003;124(1):47–56.PubMedCrossRef
100.
El-Serag HB, Aguirre TV, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett’s esophagus. Am J Gastroenterol. 2004;99(10):1877–83.PubMedCrossRef
101.
Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett’s oesophagus. Aliment Pharmacol Ther. 2008;27(4):321–6.PubMedCrossRef
102.
Hofstetter WL, Peters JH, DeMeester TR, Hagen JA, DeMeester SR, Crookes PF, et al. Long-term outcome of antireflux surgery in patients with Barrett’s esophagus. Ann Surg. 2001;234(4):532–8; discussion 538–9.
103.
O’Riordan JM, Byrne PJ, Ravi N, Keeling PW, Reynolds JV. Long-term clinical and pathologic response of Barrett’s esophagus after antireflux surgery. Am J Surg. 2004;188(1):27–33.PubMedCrossRef
104.
Monahan KJ, Youd PL, Willson P. Esophageal adenocarcinoma after Nissen’s fundoplication for Barrett’s esophagus: report of a case. Surg Today. 2010;40(12):1173–5.PubMedCrossRef
Metadata
Title
Management of Barrett’s esophageal carcinoma
Authors
Tatsuya Miyazaki
Takanori Inose
Naritaka Tanaka
Takehiko Yokobori
Shigemasa Suzuki
Daigo Ozawa
Makoto Sohda
Masanobu Nakajima
Minoru Fukuchi
Hiroyuki Kato
Hiroyuki Kuwano
Publication date
01-04-2013
Publisher
Springer Japan
Published in
Surgery Today / Issue 4/2013
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-012-0468-2

Other articles of this Issue 4/2013

Surgery Today 4/2013 Go to the issue

Original Article

A comparison between two types of limited sympathetic surgery for palmar hyperhidrosis

Case Report

Synchronous double cancers of primary hepatic adenosquamous carcinoma and hepatocellular carcinoma: report of a case

Original Article

The effectiveness and appropriate management of abdominal drains in patients undergoing elective liver resection: a retrospective analysis and prospective case series

How to Do It

Immediate reconstruction using a modified inframammary adipofascial flap after partial mastectomy

Case Report

Primary esophageal adenocarcinoma arising from heterotopic gastric mucosa: report of a case

Original Article

Preventive effect of sivelestat on postoperative respiratory disorders after thoracic esophagectomy